KLRS — Kalaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1754068 ·
Last close
$5.21
Market Cap
$123.96M
52W High
$10.69
52W Low
$4.52
ADV30
96,990
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,833,000 | -10,856,000 | 109,805,000 | 34,427,000 | 41,248,000 |
| Dec 2025 | 0 | — | -10,801,000 | -9,998,000 | 121,736,000 | 98,054,000 | 42,922,000 |
| Sep 2025 | 0 | — | -12,741,000 | -11,894,000 | 81,175,000 | 42,387,000 | 39,310,000 |
| Jun 2025 | 0 | — | -12,256,000 | -11,350,000 | 92,842,000 | 88,426,000 | 39,727,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,370,000
Investing CF
$14,983,000
Financing CF
$155,007,000
CapEx
$-17,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-31.93
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-159,999,000
Inventory
—
Receivables
—
ST Investments
$19,928,000
EBIT TTM
$-41,995,000
Pretax Income TTM
$-43,438,000
Interest Exp TTM
$1,443,000
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -46,152,000 | -43,438,000 | 121,736,000 | 42,922,000 | — | -38,370,000 |
| Dec 2024 | 0 | -51,732,000 | -69,167,000 | 6,162,000 | 102,778,000 | — | -20,670,000 |
| Dec 2023 | 0 | -13,464,000 | -14,699,000 | 3,333,000 | 48,350,000 | — | -14,132,000 |
| Dec 2022 | 0 | -14,006,000 | -15,485,000 | 3,899,000 | 34,171,000 | — | -9,779,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACOG | Alpha Cognition Inc. | $128.03M | $5.88 | — |
| ENGN | enGene Therapeutics Inc. | $117.90M | $1.76 | — |
| CRDF | Cardiff Oncology, Inc. | $132.64M | $1.94 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $133.51M | $2.33 | — |
| AGEN | AGENUS INC | $138.25M | $3.32 | — |
News headlines (Yahoo Finance, 1h cache)
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
2026-05-14 13:45 · Yahoo
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 12:00 · Yahoo
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
2026-03-17 12:00 · Yahoo
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
2026-01-28 21:05 · Yahoo
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
2025-12-17 22:59 · Yahoo
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
2025-12-17 21:01 · Yahoo
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully
2025-11-27 12:58 · Yahoo
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
2025-11-24 13:00 · Yahoo
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-11-12 13:00 · Yahoo
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
2025-11-03 12:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-05-22 19:47:34 | 2026-05-20 | Akkaraju Srinivas | Dir, 10% | P - Purchase | 4.83 | 244300 | 1179969 |